• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

形态组学可预测细胞减灭性肾切除术治疗转移性肾细胞癌的肿瘤学特征和生存情况。

Morphomics Can Predict Oncological Features and Survival of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy.

机构信息

Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan, R.O.C.

Cancer Genome Research Center, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan, R.O.C.

出版信息

Anticancer Res. 2021 Oct;41(10):5203-5211. doi: 10.21873/anticanres.15339.

DOI:10.21873/anticanres.15339
PMID:34593473
Abstract

BACKGROUND/AIM: This study analyzed the ability of body composition to predict the outcome of patients with metastatic renal cell carcinoma (RCC) who received cytoreductive nephrectomy followed by systemic therapy.

PATIENTS AND METHODS

A retrospective study was conducted from December 2010 to November 2017 in a single tertiary medical center. The medical charts and computed tomography images were reviewed. Statistical analysis included oncological features, their correlation with body composition factors, and overall survival.

RESULTS

Skeletal muscle volume was significantly higher in patients with Fuhrman grade 2 RCC than those with grade≥3. Patients with intermediate International Metastatic RCC Database Consortium risk had significantly higher BMI and skeletal muscle compared to those with poor risk. Multivariate analysis showed that increased skeletal muscle and decreased visceral adipose tissue were significant predictors of a better overall survival.

CONCLUSION

Body composition highly correlated with the oncological features of metastatic RCC and impacted survival.

摘要

背景/目的:本研究分析了体成分预测接受细胞减灭性肾切除术联合全身治疗的转移性肾细胞癌(RCC)患者预后的能力。

患者和方法

本回顾性研究于 2010 年 12 月至 2017 年 11 月在一家单中心三级医疗中心进行。对病历和 CT 图像进行了回顾。统计分析包括肿瘤特征、它们与体成分因素的相关性以及总生存期。

结果

RCC 患者的骨骼肌体积在 Fuhrman 分级 2 者中显著高于分级≥3 者。国际转移性 RCC 数据库联盟(IMDC)中危患者的 BMI 和骨骼肌明显高于低危患者。多变量分析表明,骨骼肌增加和内脏脂肪组织减少是总生存期更好的显著预测因素。

结论

体成分与转移性 RCC 的肿瘤特征高度相关,并影响生存。

相似文献

1
Morphomics Can Predict Oncological Features and Survival of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy.形态组学可预测细胞减灭性肾切除术治疗转移性肾细胞癌的肿瘤学特征和生存情况。
Anticancer Res. 2021 Oct;41(10):5203-5211. doi: 10.21873/anticanres.15339.
2
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.细胞减灭性肾切除术治疗肾细胞癌同步转移患者:来自国际转移性肾细胞癌数据库联盟的结果。
Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13.
3
Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.转移性非透明细胞肾细胞癌患者细胞减灭性肾切除术后的生存情况:一项基于人群的研究。
Eur Urol Focus. 2019 May;5(3):488-496. doi: 10.1016/j.euf.2017.11.012. Epub 2017 Dec 8.
4
Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.原发肿瘤大小对接受细胞减灭性肾切除术的转移性肾细胞癌患者预后的影响:中国中心和美国 SEER 数据库的人群研究。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211019507. doi: 10.1177/15330338211019507.
5
Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.细胞减灭性肾切除术治疗伴有静脉瘤栓的肾细胞癌。
J Urol. 2017 Aug;198(2):281-288. doi: 10.1016/j.juro.2017.03.011. Epub 2017 Mar 6.
6
The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.减瘤性肾切除术在转移性肾细胞癌中的独立肿瘤学作用:靶向治疗时代的预后特征
Urol Oncol. 2017 Apr;35(4):152.e13-152.e22. doi: 10.1016/j.urolonc.2016.10.013. Epub 2017 Jan 30.
7
Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.在靶向治疗前进行减瘤性肾切除术并取栓可提高伴有静脉瘤栓的转移性肾细胞癌患者的生存率:单中心经验
World J Surg Oncol. 2017 Jan 5;15(1):4. doi: 10.1186/s12957-016-1066-3.
8
Survival following cytoreductive nephrectomy: a comparison of existing prognostic models.细胞减灭性肾切除术的生存情况:现有预后模型的比较。
BJU Int. 2020 Dec;126(6):745-753. doi: 10.1111/bju.15160. Epub 2020 Aug 19.
9
Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.细胞减灭性肾切除术治疗下腔静脉肿瘤栓转移性肾细胞癌患者的肿瘤学结果。
Int J Clin Oncol. 2018 Jun;23(3):553-558. doi: 10.1007/s10147-017-1232-9. Epub 2018 Jan 13.
10
Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy.肾细胞癌伴脑转移:质疑细胞减灭性肾切除术的作用。
Urol Oncol. 2019 Mar;37(3):182.e9-182.e15. doi: 10.1016/j.urolonc.2018.10.021. Epub 2018 Dec 5.

引用本文的文献

1
Factors Associated With Prescription of Systemic Therapy in Real-world Patients With Metastatic Renal Cell Cancer Managed in a Rural Region.农村地区转移性肾细胞癌实际病例中全身治疗处方的相关因素
Cancer Diagn Progn. 2024 May 3;4(3):250-255. doi: 10.21873/cdp.10316. eCollection 2024 May-Jun.